Literature DB >> 8300245

Specific IgG2 antibodies to Pseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis.

G Kronborg1, T Pressler, A Fomsgaard, C Koch, N Høiby.   

Abstract

The IgG subclass antibody response to the two parts of Pseudomonas aeruginosa lipopolysaccharide; endotoxic lipid A and the O-polysaccharide, were investigated in a retrospective longitudinal study involving 16 patients with cystic fibrosis and chronic P. aeruginosa lung infection. The purpose of the study was to see if any of the IgG subclasses of either specificity could be used as prognostic markers in the development and subsequent course of the lung disease. IgG2 anti-lipid A, IgG3 anti-lipid A, and IgG2 anti-polysaccharide showed a significant positive correlation with deteriorating pulmonary function already before chronic P. aeruginosa lung infection was diagnosed as well as in subsequent years. The findings suggest antigenic exposure of the patient before chronic infection is detected by routine sputum examinations, and further support our previous findings of a critical role of the IgG subclass response in modulating the course of inflammatory lung damage in these patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8300245     DOI: 10.1007/BF01712448

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  20 in total

1.  ELISA for antibodies to lipid A, lipopolysaccharides and other hydrophobic antigens.

Authors:  M A Freudenberg; A Fomsgaard; I Mitov; C Galanos
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

2.  Prevalence and persistence of polyagglutinable Pseudomonas aeruginosa in isolates from cystic fibrosis patients.

Authors:  B Ojeniyi; N Høiby; V T Rosdahl
Journal:  APMIS       Date:  1991-02       Impact factor: 3.205

3.  Association of systemic immune complexes, complement activation, and antibodies to Pseudomonas aeruginosa lipopolysaccharide and exotoxin A with mortality in cystic fibrosis.

Authors:  R B Moss; Y P Hsu; N J Lewiston; J G Curd; H Milgrom; S Hart; B Dyer; J W Larrick
Journal:  Am Rev Respir Dis       Date:  1986-04

4.  Interaction of lipopolysaccharides and lipid A with complement.

Authors:  C Galanos; E T Rietschel; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1971-03-01

5.  [Lipoid A antibody titer in the human].

Authors:  W Marget
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

6.  Antilipopolysaccharide antibodies and differential diagnosis of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.

Authors:  A Fomsgaard; B Dinesen; G H Shand; T Pressler; N Høiby
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

7.  The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. Implications for the pathogenesis of the Pseudomonas lung lesion.

Authors:  D B Hornick; R B Fick
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

8.  Antibodies from chronically infected cystic fibrosis patients react with lipopolysaccharides extracted by new micromethods from all serotypes of Pseudomonas aeruginosa.

Authors:  A Fomsgaard; G H Shand; M A Freudenberg; C Galanos; R S Conrad; G Kronborg; N Høiby
Journal:  APMIS       Date:  1993-02       Impact factor: 3.205

9.  Immunoglobulin allotypes and IgG subclass antibody response to Pseudomonas aeruginosa antigens in chronically infected cystic fibrosis patients.

Authors:  T Pressler; J P Pandey; F Espersen; S S Pedersen; A Fomsgaard; C Koch; N Høiby
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

10.  IgG subclass antibody responses to alginate from Pseudomonas aeruginosa in patients with cystic fibrosis and chronic P. aeruginosa infection.

Authors:  T Pressler; S S Pedersen; F Espersen; N Høiby; C Koch
Journal:  Pediatr Pulmonol       Date:  1992-09
View more
  3 in total

1.  Anti-LPS IgA and IgG Can Inhibit Serum Killing of Pseudomonas aeruginosa in Patients with Cystic Fibrosis.

Authors:  Amy Pham; Emma L Ledger; Carrie F Coggon; Ian R Henderson; David W Reid; Scott C Bell; Daniel J Smith; Timothy J Wells
Journal:  Infect Immun       Date:  2021-08-30       Impact factor: 3.441

2.  Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing.

Authors:  Timothy J Wells; Deborah Whitters; Yanina R Sevastsyanovich; Jennifer N Heath; John Pravin; Margaret Goodall; Douglas F Browning; Matthew K O'Shea; Amy Cranston; Anthony De Soyza; Adam F Cunningham; Calman A MacLennan; Ian R Henderson; Robert A Stockley
Journal:  J Exp Med       Date:  2014-08-11       Impact factor: 14.307

Review 3.  The Role of Pseudomonas aeruginosa Lipopolysaccharide in Bacterial Pathogenesis and Physiology.

Authors:  Steven M Huszczynski; Joseph S Lam; Cezar M Khursigara
Journal:  Pathogens       Date:  2019-12-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.